Tag: Vitiligo
Risk for Vitiligo Increased for Transplant Recipients
Increased risk seen for those receiving allogeneic grafts and autologous grafts, as well as those with and without comorbid GVHD
Half of Patients With Newly Diagnosed Vitiligo Do Not Receive Treatment
Proportion receiving treatment within 12 months higher with more severe disease
Incidence Rate of Diagnosed Vitiligo 22.6 per 100,000 Person-Years
Vitiligo most commonly diagnosed in older adults and in Hispanic/Latino and Asian American patients
AAD: Long-Term Improvement Seen With Ruxolitinib in Vitiligo
Improvement in facial/total Vitiligo Area Scoring Index seen with continued treatment from weeks 52 to 104
Ruxolitinib Cream Results in Greater Repigmentation in Vitiligo
More patients receiving ruxolitinib have decrease of at least 75 percent from baseline in facial Vitiligo Area Scoring Index
FDA Approves First Topical Treatment for Vitiligo
Opzelura can be used twice daily in patients ages 12 years and older
Study Shows Link Between Atopic Dermatitis and Vitiligo
Subgroup analyses show significant associations between adult, childhood AD and vitiligo
Microneedling + 5-Fluorouracil Effective Vitiligo Treatment
5-fluorouracil achieved a higher percentage of repigmentation versus tacrolimus
Repigmentation of Vitiligo Seen With Tofacitinib, Phototherapy
Case reports describe repigmentation of vitiligo with facial involvement in Hispanic woman, white man
CO2 Laser + Platelet-Rich Plasma Promising Treatment for Vitiligo
However, CO2 laser, platelet-rich plasma alone show poor results
